首页> 美国卫生研究院文献>Springer Open Choice >Development of the SIOPE DIPG network registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease
【2h】

Development of the SIOPE DIPG network registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease

机译:SIOPE DIPG网络注册机构和影像库的开发:共同努力以优化对罕见和致死性疾病的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in survival. It is therefore time for international collaboration in DIPG research, to provide new hope for children, parents and medical professionals fighting DIPG. In a first step towards collaboration, in 2011, a network of biologists and clinicians working in the field of DIPG was established within the European Society for Paediatric Oncology (SIOPE) Brain Tumour Group: the SIOPE DIPG Network. By bringing together biomedical professionals and parents as patient representatives, several collaborative DIPG-related projects have been realized. With help from experts in the fields of information technology, and legal advisors, an international, web-based comprehensive database was developed, The SIOPE DIPG Registry and Imaging Repository, to centrally collect data of DIPG patients. As for April 2016, clinical data as well as MR-scans of 694 patients have been entered into the SIOPE DIPG Registry/Imaging Repository. The median progression free survival is 6.0 months (95% Confidence Interval (CI) 5.6–6.4 months) and the median overall survival is 11.0 months (95% CI 10.5–11.5 months). At two and five years post-diagnosis, 10 and 2% of patients are alive, respectively. The establishment of the SIOPE DIPG Network and SIOPE DIPG Registry means a paradigm shift towards collaborative research into DIPG. This is seen as an essential first step towards understanding the disease, improving care and (ultimately) cure for children with DIPG.Electronic supplementary materialThe online version of this article (doi:10.1007/s11060-016-2363-y) contains supplementary material, which is available to authorized users.
机译:弥漫性桥脑神经胶质瘤(DIPG)是一种罕见且致命的儿童恶性肿瘤。经过40年的大多为单中心,通常为非随机试验且患者包裹体可变的试验后,生存率没有改善。因此,现在是进行DIPG研究的国际合作的时候了,为与DIPG斗争的儿童,父母和医疗专业人员提供新的希望。迈向合作的第一步,是在2011年,欧洲小儿肿瘤学会(SIOPE)脑肿瘤小组内部建立了由DIPG领域的生物学家和临床医生组成的网络:SIOPE DIPG网络。通过将生物医学专业人士和父母作为患者代表聚集在一起,已经实现了几个与DIPG相关的合作项目。在信息技术领域的专家和法律顾问的帮助下,开发了一个基于Web的国际综合数据库SIOPE DIPG注册和影像库,以集中收集DIPG患者的数据。截至2016年4月,已将694位患者的临床数据和MR扫描结果输入到SIOPE DIPG注册/影像存储库中。中位无进展生存期为6.0个月(95%置信区间(CI)5.6–6.4个月),中位总生存期为11.0个月(95%CI为10.5-11.5个月)。在诊断后的第二年和第五年,分别有10%和2%的患者还活着。 SIOPE DIPG网络和SIOPE DIPG注册中心的建立意味着向DIPG合作研究的范式转变。这被视为了解DIPG儿童疾病,改善护理和(最终)治愈的必不可少的第一步。电子补充材料本文的在线版本(doi:10.1007 / s11060-016-2363-y)包含补充材料,可供授权用户使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号